Axovant Sciences

AXGT NASDAQ
7.38
-0.01
-0.14%
After Hours: 7.38 0 0.00% 16:00 05/20 EDT
Open
7.55
Prev Close
7.39
High
7.88
Low
7.16
Volume
257.15K
Avg Vol (3M)
304.56K
52 Week High
52.72
52 Week Low
7.16
% Turnover
1.13%
Market Cap
168.12M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

Axovant Gene Therapies Ltd., formerly Axovant Sciences Ltd., is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. Its AXO-Lenti-PD is an in vivo lentiviral gene therapy investigational product candidate and being developed for the one-time treatment of Parkinson’s disease.
MORE >

Recently

Name
Price
%Change